Digest Network Come funziona
Network
/
Società
Ag
Non verificato

Agomab Therapeutics NV

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

5 comunicati stampa

Guarda tutti i comunicati
10/04/2025
Eventi
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Late-Breaking Interim STENOVA Data for AGMB-129 in Fibrostenosing Crohn’s to be Presented at Digestive Disease Week® 2025
Fonte
Agomab Therapeutics NV
Emittente
Business Wire
1.00
0
10/03/2025
Industria
Salute
Scienza
Medicina - Varie
Farmaceutica
Biotecnologia
Agomab Announces Positive Topline Phase 2a Interim Results for AGMB-129 in Fibrostenosing Crohn’s Disease
Fonte
Agomab Therapeutics NV
Emittente
Business Wire
1.00
0
25/10/2024
Industria
Salute
Scienza
Medicina - Varie
Farmaceutica
Biotecnologia
Agomab Announces $89 Million Series D Financing to Support Broad Fibrosis-Focused Pipeline
Fonte
Agomab Therapeutics NV
Emittente
Business Wire
1.00
0
11/07/2024
Mercato del lavoro
Salute
Scienza
Farmaceutica
Biotecnologia
Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer
Fonte
Agomab Therapeutics NV
Emittente
Business Wire
1.00
0
09/07/2024
Mercato del lavoro
Salute
Scienza
Farmaceutica
Biotecnologia
Agomab Appoints Industry Veteran David Epstein as Chairman of its Board of Directors
Fonte
Agomab Therapeutics NV
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0